Publications by authors named "Mohammad Amin Nezami"
Article Synopsis
- The study examines the use of anti-HER2 therapy in patients with HER2-amplified pancreatic ductal adenocarcinoma (PDAC), noting that it is currently the only FDA-approved targeted therapy for this type of cancer.
- It highlights two case studies where patients treated with anti-HER2 therapy experienced positive outcomes, indicating a potential benefit in some cases despite mixed results in previous studies.
- The research also identifies that certain genetic alterations may contribute to resistance against anti-HER2 therapies, suggesting a need for further investigation into these mechanisms to improve treatment effectiveness.
Purpose: Gene fusions are established oncogenic drivers and emerging therapeutic targets in advanced colorectal cancer. This study aimed to detail the frequencies and clinicopathological features of gene fusions in colorectal cancer using a circulating tumor DNA assay.
Methods: Circulating tumor DNA samples in patients with advanced colorectal cancer were analyzed at 4,581 unique time points using a validated plasma-based multigene assay that includes assessment of fusions in , , , , , and Associations between fusions and clinicopathological features were measured using Fisher's exact test.
Purpose: PARP inhibitors (PARPi) are efficacious in multiple cancers harboring germline (and possibly somatic) mutations. Acquired reversions can restore function, causing resistance to PARPi and/or platinum-based chemotherapy. The optimal method of identifying patients with germline, somatic, and/or reversion mutations in has not been established.
View Article and Find Full Text PDF